Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IQM | 82.06 | 2.89 | +3.65% |
| Franklin Intelligent Machines ETF (IQM) | |||
| PCN | 11.07 | 0.16 | +1.47% |
| PIMCO Corporate & Income Strategy Fund | |||
| FLXI | 48.00 | N/A | N/A |
| Invesco Flexible Income ETF (FLXI) | |||
| GLDM | 80.41 | -0.65 | -0.80% |
| SPDR Gold Minishares Trust of beneficial interest (GLDM) | |||
| FXG | 62.33 | -0.76 | -1.20% |
| First Trust Consumer Staples AlphaDEX Fund (FXG) | |||
A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To BNTC | 1D Price Change % | ||
|---|---|---|---|---|
| BNTC | 100% | +10.42% | ||
| VIR - BNTC | 49% Loosely correlated | +10.80% | ||
| EDIT - BNTC | 47% Loosely correlated | +0.78% | ||
| DYN - BNTC | 46% Loosely correlated | +4.09% | ||
| TSHA - BNTC | 46% Loosely correlated | +5.87% | ||
| GNLX - BNTC | 45% Loosely correlated | +7.69% | ||
More | ||||
a biotechnology, research and development company
Industry Biotechnology
The 50-day moving average for BNTC moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
BNTC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BNTC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNTC's RSI Indicator exited the oversold zone, 21 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNTC as a result. In 83 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for BNTC just turned positive on October 20, 2026. Looking at past instances where BNTC's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
Following a +1.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 226 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BNTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.880) is normal, around the industry mean (3.498). P/E Ratio (-9.735) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.